PCSK9 and endothelial dysfunction: Evidence suggests that inhibiting PCSK9 can mitigate endothelial dysfunction and reduce the size of atherosclerotic lesions, offering a promising avenue for therapeutic interventions in atherosclerotic diseases [100].